Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade C 9.55 2.69% 0.25
ABUS closed up 2.69 percent on Tuesday, September 18, 2018, on 50 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ABUS trend table...

Date Alert Name Type % Chg
Sep 18 20 DMA Resistance Bearish 0.00%
Sep 17 Fell Below 20 DMA Bearish 2.69%
Sep 17 MACD Bearish Signal Line Cross Bearish 2.69%
Sep 14 20 DMA Support Bullish -0.52%
Sep 13 Narrow Range Bar Range Contraction -1.04%
Sep 13 NR7 Range Contraction -1.04%
Sep 13 Inside Day Range Contraction -1.04%
Sep 12 Fell Below 50 DMA Bearish 0.00%
Sep 12 Multiple of Ten Bearish Other 0.00%
Sep 11 50 DMA Support Bullish -5.91%

Older signals for ABUS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.6
52 Week Low 4.3
Average Volume 483,777
200-Day Moving Average 6.7547
50-Day Moving Average 10.104
20-Day Moving Average 9.57
10-Day Moving Average 10.01
Average True Range 0.6305
ADX 14.11
+DI 21.3265
-DI 22.6563
Chandelier Exit (Long, 3 ATRs ) 9.3585
Chandelier Exit (Short, 3 ATRs ) 10.5415
Upper Bollinger Band 10.8682
Lower Bollinger Band 8.2718
Percent B (%b) 0.49
BandWidth 27.130617
MACD Line 0.0214
MACD Signal Line 0.0567
MACD Histogram -0.0353
Fundamentals Value
Market Cap 525.5 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -1.88
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.15
Resistance 3 (R3) 10.12 9.88 10.05
Resistance 2 (R2) 9.88 9.73 9.90 10.02
Resistance 1 (R1) 9.72 9.64 9.80 9.75 9.98
Pivot Point 9.48 9.48 9.53 9.50 9.48
Support 1 (S1) 9.32 9.33 9.40 9.35 9.12
Support 2 (S2) 9.08 9.24 9.10 9.08
Support 3 (S3) 8.92 9.08 9.05
Support 4 (S4) 8.95